Incanthera PLC - develops technologies in dermatology and oncology - Pretax loss widens 20% to GBP615,000 in the six months to September 30, from GBP511,000 a year ago. Declares no revenue in either half-year. Looking ahead, the company says: "The post-balance sheet event of the commercial skincare deal is expected to transform Incanthera into a company with significant revenues and profits, generating free cash flow from roll out in Q2 2024." On Monday, Incanthera announced that its Swiss subsidiary Skin & Cell AG signed a deal with Marionnaud, part of the AS Watson Group, to make the skincare brand available exclusively initially in Marionnaud's stores in Switzerland and Austria from the second quarter of next year. Later in 2024, the products will be rolled out in the remaining 1,100 Marionnaud stores across Europe.
Current stock price: 6.95 pence, up 6.9% on Thursday
12-month change: up 2.2%
By Tom Budszus, Alliance News slot editor
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.